November 18, 2026
Health news, explained with evidence
LIVE

Study Examines Diabetes Medications and Lung Inflammation Risk in Cancer Immunotherapy Patients

🧠 AI Analysis 2 min read 👁 6

Researchers utilizing a Japanese claims database investigated whether baseline glucose-lowering drugs affect the risk of immune checkpoint inhibitor-induced pneumonitis in type 2 diabetes patients.

🧠AI Analysis

Key points

  • Retrospective cohort study analyzed 21,738 cancer patients with type 2 diabetes.
  • Primary analysis found no clear link between baseline glucose-lowering drugs and pneumonitis.
  • Concomitant immunotherapy and younger age showed varied associations with the lung complication risk.

A recent retrospective cohort study published in Scientific Reports has explored whether baseline glucose-lowering treatments are linked to the development of immune checkpoint inhibitor-induced pneumonitis among cancer patients with type 2 diabetes. Led by researchers including Yoko Kobayashi and Takeshi Horii from Musashino University and Kitasato University in Japan, the investigation analyzed data from a large-scale claims database covering the period from April 2014 to October 2023.

Study Findings and Key Observations

The study reviewed 21,738 eligible patients newly starting immune checkpoint inhibitor-based chemotherapy. Out of this cohort, 1,164 individuals, representing 5.4 percent, experienced immune-related pneumonitis. In the primary multivariable logistic regression analysis, no specific class of glucose-lowering medication taken at the start of immunotherapy showed a statistically significant link to the lung complication. For instance, the adjusted odds ratio for DPP-4 inhibitors stood at 0.89.

  • Concomitant use of immune checkpoint inhibitors was associated with increased odds of developing pneumonitis, showing an odds ratio of 1.40.
  • Older age demonstrated an inverse association, with lower odds observed per 10-year increase in age (odds ratio of 0.82).
  • A sensitivity analysis focusing on cases requiring hospitalization suggested potential associations with certain drug classes like SGLT2 inhibitors and insulin, though authors noted these required careful interpretation due to fewer events.
What to know: Baseline use of diabetes medications did not demonstrate a clear protective or harmful association with immunotherapy-induced lung inflammation in the primary analysis. Readers are encouraged to consult a qualified healthcare provider for personal medical decisions and treatment management.

Source Nature Health Sciences — nature.com/articles/s41598-026-80275-w ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.